Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Mar;33(3):605-7.
doi: 10.2337/dc09-0455. Epub 2009 Dec 15.

Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial

Priscilla A Hollander  1 , Aslam Amod, León E Litwak, Umesh Chaudhari; ARPEGGIO Study Group
Affiliations
Randomized Controlled Trial

Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial

Priscilla A Hollander et al. Diabetes Care. 2010 Mar.

Abstract

OBJECTIVE To examine the efficacy and safety of rimonabant, a selective cannabinoid receptor type-1 antagonist, in patients with type 2 diabetes receiving insulin monotherapy. RESEARCH DESIGN AND METHODS Patients (n = 368; A1C > or =7%) were randomized to 20 mg/day rimonabant or placebo in this 48-week, double-blind, placebo-controlled multicenter trial. Change in baseline A1C to week 48 (primary outcome) and changes in body weight, waist circumference, and lipid levels (secondary outcomes) were assessed. RESULTS Rimonabant significantly reduced baseline A1C versus placebo (-0.89 vs. -0.24%; P < 0.0001), and significantly greater improvements were observed in cardiometabolic risk factors. More rimonabant patients achieved >10% reduction in mean total daily insulin dose versus placebo (P = 0.0012), and fewer required rescue medication (P < 0.0001). Hypoglycemia, nausea, dizziness, anxiety, and depression were more frequent with rimonabant. CONCLUSIONS Rimonabant improved glycemic control and cardiometabolic risk factors in patients with type 2 diabetes receiving insulin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A: Change in A1C over time. B: Change in A1C according to baseline level. C: change in body weight over time.
See this image and copyright information in PMC

References

    1. International Diabetes Federation. Clinical Guidelines Task Force: global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23:579–593 - PubMed
    1. American Diabetes Association. Standards of medical care in diabetes, 2007. Diabetes Care 2007;30(Suppl. 1):S4–S41 - PubMed
    1. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice 2007;13(Suppl. 1):3–68 - PubMed
    1. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P: Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002;25:1033–1041 - PubMed
    1. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73–100 - PubMed

Publication types

MeSH terms